The evolution of heart failure with reduced ejection fraction pharmacotherapy: What do we have and where are we going?

Ahmed Selim, Ronald Zolty, Ioannis S Chatzizisis

Research output: Contribution to journalReview article

2 Citations (Scopus)

Abstract

Cardiovascular diseases represent a leading cause of mortality and increased healthcare expenditure worldwide. Heart failure, which simply describes an inability of the heart to meet the body's needs, is the end point for many other cardiovascular conditions. The last three decades have witnessed significant efforts aiming at the discovery of treatments to improve the survival and quality of life of patients with heart failure; many were successful, while others failed. Given that most of the successes in treating heart failure were achieved in patients with reduced left ventricular ejection fraction (HFrEF), we constructed this review to look at the recent evolution of HFrEF pharmacotherapy. We also explore some of the ongoing clinical trials for new drugs, and investigate potential treatment targets and pathways that might play a role in treating HFrEF in the future.

Original languageEnglish (US)
Pages (from-to)67-82
Number of pages16
JournalPharmacology and Therapeutics
Volume178
DOIs
StatePublished - Oct 2017

Fingerprint

Heart Failure
Drug Therapy
Health Expenditures
Stroke Volume
Cardiovascular Diseases
Quality of Life
Clinical Trials
Delivery of Health Care
Survival
Mortality
Therapeutics
Pharmaceutical Preparations

Keywords

  • Heart failure
  • Novel drugs
  • Pharmacotherapy
  • Reduced ejection fraction

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this

The evolution of heart failure with reduced ejection fraction pharmacotherapy : What do we have and where are we going? / Selim, Ahmed; Zolty, Ronald; Chatzizisis, Ioannis S.

In: Pharmacology and Therapeutics, Vol. 178, 10.2017, p. 67-82.

Research output: Contribution to journalReview article

@article{2da63e017a6f41d5b72d0becb41b4ac5,
title = "The evolution of heart failure with reduced ejection fraction pharmacotherapy: What do we have and where are we going?",
abstract = "Cardiovascular diseases represent a leading cause of mortality and increased healthcare expenditure worldwide. Heart failure, which simply describes an inability of the heart to meet the body's needs, is the end point for many other cardiovascular conditions. The last three decades have witnessed significant efforts aiming at the discovery of treatments to improve the survival and quality of life of patients with heart failure; many were successful, while others failed. Given that most of the successes in treating heart failure were achieved in patients with reduced left ventricular ejection fraction (HFrEF), we constructed this review to look at the recent evolution of HFrEF pharmacotherapy. We also explore some of the ongoing clinical trials for new drugs, and investigate potential treatment targets and pathways that might play a role in treating HFrEF in the future.",
keywords = "Heart failure, Novel drugs, Pharmacotherapy, Reduced ejection fraction",
author = "Ahmed Selim and Ronald Zolty and Chatzizisis, {Ioannis S}",
year = "2017",
month = "10",
doi = "10.1016/j.pharmthera.2017.03.011",
language = "English (US)",
volume = "178",
pages = "67--82",
journal = "Pharmacology and Therapeutics",
issn = "0163-7258",
publisher = "Elsevier Inc.",

}

TY - JOUR

T1 - The evolution of heart failure with reduced ejection fraction pharmacotherapy

T2 - What do we have and where are we going?

AU - Selim, Ahmed

AU - Zolty, Ronald

AU - Chatzizisis, Ioannis S

PY - 2017/10

Y1 - 2017/10

N2 - Cardiovascular diseases represent a leading cause of mortality and increased healthcare expenditure worldwide. Heart failure, which simply describes an inability of the heart to meet the body's needs, is the end point for many other cardiovascular conditions. The last three decades have witnessed significant efforts aiming at the discovery of treatments to improve the survival and quality of life of patients with heart failure; many were successful, while others failed. Given that most of the successes in treating heart failure were achieved in patients with reduced left ventricular ejection fraction (HFrEF), we constructed this review to look at the recent evolution of HFrEF pharmacotherapy. We also explore some of the ongoing clinical trials for new drugs, and investigate potential treatment targets and pathways that might play a role in treating HFrEF in the future.

AB - Cardiovascular diseases represent a leading cause of mortality and increased healthcare expenditure worldwide. Heart failure, which simply describes an inability of the heart to meet the body's needs, is the end point for many other cardiovascular conditions. The last three decades have witnessed significant efforts aiming at the discovery of treatments to improve the survival and quality of life of patients with heart failure; many were successful, while others failed. Given that most of the successes in treating heart failure were achieved in patients with reduced left ventricular ejection fraction (HFrEF), we constructed this review to look at the recent evolution of HFrEF pharmacotherapy. We also explore some of the ongoing clinical trials for new drugs, and investigate potential treatment targets and pathways that might play a role in treating HFrEF in the future.

KW - Heart failure

KW - Novel drugs

KW - Pharmacotherapy

KW - Reduced ejection fraction

UR - http://www.scopus.com/inward/record.url?scp=85016777844&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85016777844&partnerID=8YFLogxK

U2 - 10.1016/j.pharmthera.2017.03.011

DO - 10.1016/j.pharmthera.2017.03.011

M3 - Review article

C2 - 28336474

AN - SCOPUS:85016777844

VL - 178

SP - 67

EP - 82

JO - Pharmacology and Therapeutics

JF - Pharmacology and Therapeutics

SN - 0163-7258

ER -